ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 935

Adenosine A2A Receptor Activates The Pro-Fibrotic Wnt / β-Catenin Signaling In Human Dermal Fibroblasts

Miguel Perez-Aso1 and Bruce N. Cronstein2, 1Department of Translational Medicine, New York University School of Medicine, New York, NY, 2Internal Medicine, NYU School of Medicine, Division of Rheumatology, New York, NY

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Adenosine receptors, collagen and fibroblasts

  • Tweet
  • Email
  • Print
Session Information

Title: Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis I

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Upon adenosine formation in stress conditions, the adenosine A2A Receptor (A2AR) activation promotes wound healing, but it is also detrimental in fibrotic conditions such as scarring, scleroderma and liver fibrosis. Although we have previously shown that the A2AR regulates scarring and fibrosis by fine-tuning the collagen1 to collagen3 balance in human dermal fibroblasts, the intracellular pathway leading to collagen production upon A2AR activation remains unclear. β-catenin is a central mediator of pro-fibrotic Wnt signaling in systemic sclerosis (Beyer et al. 2012) and the pro-fibrotic growth factor TGF-β1 targets the β-catenin pathway (Caraci et al. 2008). We therefore sought to determine whether A2AR stimulates Wnt / β-catenin signaling in human dermal fibroblasts.

Methods:

Cells were stimulated for 24h with the specific A2AR agonist CGS21680, in the presence or absence of the A2AR antagonist SCH58211. β-catenin was knock-down with siRNA and collagen1, collagen3 and β-catenin expression were analyzed by western-blotting. Subcellular distribution of β-catenin was studied by cellular fractionation and confocal microscopy. 

Results:

The A2A agonist CGS21680 stimulated, in a dose-dependent fashion, a significant increase in β-catenin expression (increase over non-stimulated control: CGS21680 0.1μM 139.6±10.3%, P<0.01 n=5; 1μM 163.7±18.8%, P<0.001 n=3; 10μM 151.6±7.1%, P<0.001 n=5) and preincubation with the A2AR antagonist SCH21680 1μM prevented this effect (two-way ANOVA P<0.01, n=5). Subcellular fractionation after incubation with CGS21680 (1μM) showed a preferential increase of β-catenin in the nucleus, as assessed by Western Blot Analysis and confocal images demonstrate colocalization of the nuclear marker DAPI and β-catenin after A2AR stimulation. As expected, CGS21680 1μM stimulated an increase of both collagen1 (1.4 and 2.5 fold increase over control) and collagen3 (2.8 and 2.2 fold increase over control) but, interestingly, β-catenin knock-down prevented the CGS21680-mediated increase in collagen3, but not collagen1. 

Conclusion:

These results strongly support the hypothesis that activation of the A2AR leads to cross-talk with the pro-fibrotic Wnt / β-catenin signaling system. These findings suggest a mechanism for changes in the collagen1:collagen3 ratio in animal models of hypertrophic scars and scleroderma in which A2AR blockade or deletion prevents fibrosis and in which adenosine concentrations are dramatically increased.


Disclosure:

M. Perez-Aso,
None;

B. N. Cronstein,

Canfite Pharma,

1,

NIH, Gilead, Takeda, AstraZeneca,

2,

NYU School of Medicine,

3,

Merck-SeronoBristol-Myers Squibb, Novartis, CanFite Biopharmaceuticals, Cypress Laboratories, Regeneron (Westat, DSMB), Endocyte, Protalex, Allos, Inc., Savient, Gismo Therapeutics, Antares Pharmaceutical, Medivector,

5,

Multiple patents on adenosine receptors and bone metabolism, pharmacology,

9.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/adenosine-a2a-receptor-activates-the-pro-fibrotic-wnt-%ce%b2-catenin-signaling-in-human-dermal-fibroblasts/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology